Matthew Kaplan
Stock Analyst at Ladenburg Thalmann
(2.77)
# 1,724
Out of 5,163 analysts
25
Total ratings
60.87%
Success rate
17.81%
Average return
Main Sectors:
Stocks Rated by Matthew Kaplan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $319 → $344 | $536.12 | -35.84% | 9 | Oct 31, 2024 | |
| URGN UroGen Pharma | Maintains: Buy | $48 → $54 | $18.45 | +189.97% | 1 | Jun 14, 2024 | |
| TGTX TG Therapeutics | Maintains: Buy | $39 → $40 | $27.96 | +43.06% | 3 | May 2, 2024 | |
| LQDA Liquidia | Maintains: Buy | $15 → $30 | $36.66 | -18.17% | 2 | Dec 21, 2023 | |
| ARDX Ardelyx | Maintains: Buy | $7.5 → $8.5 | $5.78 | +47.06% | 4 | Aug 3, 2023 | |
| KPRX Kiora Pharmaceuticals | Reiterates: Buy | $1,071 | $2.09 | +51,144.02% | 2 | Feb 8, 2023 | |
| XAIR Beyond Air | Maintains: Buy | $340 → $460 | $0.82 | +55,997.56% | 1 | Jun 29, 2022 | |
| LPCN Lipocine | Upgrades: Buy | $51 | $7.34 | +594.82% | 1 | Dec 10, 2020 | |
| COGT Cogent Biosciences | Initiates: Buy | $16 | $34.00 | -52.94% | 1 | Oct 14, 2020 | |
| TARA Protara Therapeutics | Initiates: Buy | $45 | $5.26 | +755.51% | 1 | Jan 22, 2020 |
United Therapeutics
Oct 31, 2024
Maintains: Buy
Price Target: $319 → $344
Current: $536.12
Upside: -35.84%
UroGen Pharma
Jun 14, 2024
Maintains: Buy
Price Target: $48 → $54
Current: $18.45
Upside: +189.97%
TG Therapeutics
May 2, 2024
Maintains: Buy
Price Target: $39 → $40
Current: $27.96
Upside: +43.06%
Liquidia
Dec 21, 2023
Maintains: Buy
Price Target: $15 → $30
Current: $36.66
Upside: -18.17%
Ardelyx
Aug 3, 2023
Maintains: Buy
Price Target: $7.5 → $8.5
Current: $5.78
Upside: +47.06%
Kiora Pharmaceuticals
Feb 8, 2023
Reiterates: Buy
Price Target: $1,071
Current: $2.09
Upside: +51,144.02%
Beyond Air
Jun 29, 2022
Maintains: Buy
Price Target: $340 → $460
Current: $0.82
Upside: +55,997.56%
Lipocine
Dec 10, 2020
Upgrades: Buy
Price Target: $51
Current: $7.34
Upside: +594.82%
Cogent Biosciences
Oct 14, 2020
Initiates: Buy
Price Target: $16
Current: $34.00
Upside: -52.94%
Protara Therapeutics
Jan 22, 2020
Initiates: Buy
Price Target: $45
Current: $5.26
Upside: +755.51%